Loading
Dialysis and Renal Disease Management · Journal article
Neurological Sciences · September 11, 2026
Raises a question worth testing. It does not answer one.
This narrative synthesis proposes an integrated kidney-brain tissue-environment framework to explain cognitive impairment in CKD through converging vascular, inflammatory, barrier, and neurofluid mechanisms. The authors identify choroid plexus enlargement, altered cerebrospinal fluid dynamics, reduced DTI-ALPS indices, and elevated plasma phosphorylated tau and other Alzheimer-related biomarkers in CKD, but emphasize that human evidence is predominantly cross-sectional and does not establish temporal or causal sequencing. The framework is offered as testable rather than causal and highlights the need for kidney function adjustment in cognitive and biomarker interpretation.
Narrative synthesis and integrative framework. Published studies on CKD, cognitive impairment, and related imaging and biomarker findings; no primary enrollment or patient population.
CKD is associated with choroid plexus enlargement, lower DTI-ALPS indices, altered CSF-related signal coupling, and neurovascular decoupling in human studies Reduced kidney function may increase plasma phosphorylated tau, amyloid-β, neurofilament light chain, and glial fibrillary acidic protein concentrations Human evidence is predominantly cross-sectional and does not establish temporal or causal sequencing
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should regard CKD as an active modifier of cognitive phenotype and interpret neuroimaging and plasma biomarker findings in the context of reduced kidney function. Adjustment for kidney function and reporting of dialysis status is recommended when evaluating cognitive decline and Alzheimer-related biomarkers in this population.
A narrative synthesis proposing an integrative framework for kidney-brain interactions in cognitive decline, raising mechanistic questions rather than testing causal hypotheses with empirical evidence.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should regard CKD as an active modifier of cognitive phenotype and interpret neuroimaging and plasma biomarker findings in the context of reduced kidney function. Adjustment for kidney function and reporting of dialysis status is recommended when evaluating cognitive decline and Alzheimer-related biomarkers in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Cognitive impairment is common in chronic kidney disease (CKD), yet vascular, uremic, dialysis-related, and neurodegenerative mechanisms are often considered separately. We propose an integrated kidney-brain tissue-environment framework to support neurological interpretation of cognitive, imaging, and biomarker findings in CKD. METHODS: We conducted a narrative synthesis of clinical, neuroimaging, experimental, and biomarker studies retrieved from PubMed/MEDLINE, Embase, Scopus, and Web of Science through June 2026, focusing on barrier dysfunction, choroid plexus remodeling, cerebrospinal fluid dynamics, neurovascular coupling, white-matter injury, glymphatic-related imaging markers, and Alzheimer disease-related plasma biomarkers. RESULTS: CKD is associated with convergent vascular, inflammatory, toxic, barrier, and neurofluid-related abnormalities that may contribute to a mixed cognitive phenotype. Human studies report choroid plexus enlargement, lower diffusion tensor image analysis along the perivascular space (DTI-ALPS) indices, altered cerebrospinal fluid-related signal coupling, and neurovascular decoupling; however, evidence is predominantly cross-sectional and does not establish temporal or causal sequencing. Choroid plexus enlargement is morphologically nonspecific, while DTI-ALPS reflects a composite tissue environment rather than direct glymphatic flow. Reduced kidney function may also increase plasma phosphorylated tau, amyloid-β, neurofilament light chain, and glial fibrillary acidic protein concentrations. Ratio-based measures may attenuate, but do not uniformly eliminate, kidney-related confounding. CONCLUSIONS: CKD should be regarded as an active modifier of cognitive phenotype, neuroimaging interpretation, and plasma biomarker assessment. The proposed framework is testable rather than causal and supports reporting kidney function, dialysis context, and multimodal markers when evaluating cognitive decline.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.